Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) and Novo Nordisk announced initiation of a Phase 1 study of LX9851, an oral non-incretin candidate for obesity.
Lexicon earned a second $10 million milestone in 2026, may earn a third this year, and is eligible for up to $1 billion in total payments plus tiered royalties. The 96-subject trial is expected to complete in Q1 2027.
AI-generated analysis. Not financial advice.
Positive
- Second $10M milestone earned following initial Phase 1 dosing
- Eligible for up to $1B in upfront and milestone payments
- Tiered royalties on net sales provide upside if commercialized
- Phase 1 initiated with 96 people with overweight or obesity
- Trial completion targeted in Q1 2027
Negative
- Early-stage program (Phase 1): efficacy and safety in larger populations unproven
- Material commercial payments depend on future development and sales milestones
News Market Reaction – LXRX
On the day this news was published, LXRX gained 5.13%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.7% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $37M to the company's valuation, bringing the market cap to $749.91M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LXRX fell 3.7% pre-news with high volume. Peers showed mixed moves: FULC -3.84%, INBX -4.65%, SLDB -5.76%, while ATXS rose 0.8%. Momentum data show both up and down moves across names, pointing to stock-specific dynamics rather than a clean sector-wide trend.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 21 | End-of-Phase 2 FDA | Positive | +19.1% | FDA raised no objections to advancing pilavapadin into Phase 3. |
| Dec 05 | HFpEF adipose data | Neutral | -1.4% | Presentation of sotagliflozin adipose distribution data at CVCT 2025. |
| Nov 08 | HFpEF efficacy data | Positive | +13.6% | Statistically significant HFpEF benefits without diabetes in SOTA P CARDIA trial. |
| Mar 03 | Phase 2b PROGRESS topline | Negative | -58.2% | PROGRESS met objectives but missed primary endpoint statistical significance. |
| Mar 02 | PROGRESS results preview | Neutral | -58.2% | Announcement of upcoming Phase 2b PROGRESS topline results webcast. |
Clinical trial headlines have produced volatile moves for LXRX, including both strong rallies and sharp drawdowns, showing that data and regulatory nuances materially sway reactions.
Over the past year, Lexicon’s story has centered on clinical and regulatory progress across multiple programs. Clinical-trial news included positive HFpEF data for sotagliflozin and an End-of-Phase 2 FDA meeting clearing pilavapadin for Phase 3 design talks, alongside a sharply negative reaction to Phase 2b PROGRESS topline results. Today’s LX9851 Phase 1 initiation builds on that pipeline narrative and follows the 10-K’s description of LX9851’s licensing to Novo Nordisk with substantial potential milestone and royalty economics.
Historical Comparison
In the last 12 months, Lexicon issued 5 clinical-trial headlines averaging a -17.01% next-day move, with both strong gains and steep losses. The LX9851 Phase 1 start continues this pattern of market sensitivity to clinical updates.
Clinical news shows progression from Phase 2b pilavapadin data to an End-of-Phase 2 FDA meeting, plus expanding sotagliflozin datasets, now complemented by LX9851’s transition into Phase 1 under Novo Nordisk.
Market Pulse Summary
The stock moved +5.1% in the session following this news. A strong positive reaction aligns with the significance of a first-in-class obesity candidate entering Phase 1 under a major partner. Past clinical headlines produced large moves, including both rallies and steep declines, so volatility around LX9851 updates would not be unusual. Investors could weigh the $10 million milestones and eligibility for up to $1 billion in payments against trial execution risk and broader biotech sentiment.
Key Terms
phase 1 medical
placebo medical
pharmacokinetics medical
pharmacodynamics medical
non-incretin medical
AI-generated analysis. Not financial advice.
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
Lexicon has earned a second of three potential
THE WOODLANDS, Texas, March 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and Novo Nordisk A/S today announced that Novo Nordisk has initiated a Phase 1 study with LX9851, a first-in-class, oral non-incretin development candidate.
In March 2025, Lexicon signed an exclusive license agreement with Novo Nordisk for LX9851 in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications.
Lexicon has earned a second
“We are thrilled with the progress of the Novo Nordisk team on initiating the clinical development of LX9851,” said Mike Exton, CEO and director of Lexicon. “The talented team at Novo Nordisk has recognized the significant potential for LX9851, a novel, oral candidate for obesity and has moved swiftly to advance the program in its pipeline. We believe LX9851 has the potential to become a differentiated approach in the next phase of treatments for obesity and metabolic disease.”
“We are excited about the potential of LX9851 and pleased to take it into clinical testing to further explore the potential of the candidate,” said Jacob Sten Petersen, Senior Vice President and Head of Global Research at Novo Nordisk. “LX9851 offers a novel approach to the treatment of obesity and related metabolic conditions. It is an important addition to our pipeline of potential treatment options as we look to meet the diverse needs of people living with obesity, diabetes and their associated comorbidities.”
The Phase 1 study is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in 96 people with overweight or obesity. The trial is expected to be completed in the first quarter of 2027.
About LX9851
LX9851, discovered by Lexicon and in development by Novo Nordisk, is a potent and selective oral small molecule inhibitor of Acyl CoA Synthetase 5 (ACSL5). ACSL5 plays a key role in the metabolic pathway which regulates fat accumulation and energy balance. Additionally, LX9851 may activate the ileal brake mechanism leading to increased satiety by delaying gastric emptying and suppressing appetite. Preclinical in vivo efficacy data presented at Obesity Week 2024 show that LX9851, when combined with semaglutide, significantly reduced weight, food intake and fat mass compared to semaglutide alone. Separately, LX9851 mitigated weight regain and had positive effects on liver steatosis when introduced after semaglutide discontinuation.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to the preclinical and clinical development of LX9851, Lexicon’s financial position and long-term outlook on its business, growth and future operating results, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025 and other subsequent disclosure documents filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
